Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

St. Louis, Missouri 63110


The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people. NAFLD, which is common in obese people, occurs when the liver has too much fat.

Study summary:

Non-alcoholic fatty liver disease (NAFLD) affects about 20% of adults in the United States. The prevalence of NAFLD is four to five times higher in obese than lean persons and is associated with insulin resistance and the metabolic syndrome. Decreasing calorie intake and increasing physical activity has been recommended as primary therapy for NAFLD, but the independent effect of aerobic exercise is unknown. The current exercise guidelines for disease prevention and weight management range from 150 min/wk, recommended by the Centers for Disease Control and the American College of Sports Medicine, to 300 min/wk, recommended by the Institute of Medicine. However, it is not known whether aerobic exercise alone can improve NAFLD, and which recommended dose of exercise might have the most beneficial effects. The purpose of this proposal is to determine the effect of two levels of aerobic exercise on: 1) hepatic fat content; 2) hepatic lipoprotein kinetics; 3) insulin sensitivity; 4) plasma inflammatory markers; and 5) potential cellular mechanism that regulate insulin action and inflammation. We hypothesize that aerobic exercise will decrease hepatic fat content, improve hepatic, skeletal muscle, and adipose tissue insulin sensitivity, and decrease inflammation in a dose-dependent fashion. The results from this study will help determine exercise guidelines for obese patients with NAFLD, and lay the groundwork for future studies evaluating the effects of exercise on metabolic diseases associated with obesity. This proposal involves conducting a randomized controlled trial that will randomize obese subjects with NAFLD (> 5% hepatic fat content) to one of three groups: Group 1 (Control, no exercise), Group 2 (Low-Dose Aerobic Exercise- 150 min/wk of supervised exercise performed at 45-55% of O2 max), and Group 3 (Moderate-Dose Aerobic Exercise - 300min/wk of supervised exercise performed at 45-55% of O2 max) to determine the effects of low and moderate doses of aerobic exercise.


Inclusion Criteria: - Age 18-65 with Nonalcoholic Fatty Liver Disease as determined by MRS Exclusion Criteria: - Medical History - Diabetes - Heart Disease - Asthma/Lung disease - Injury that prevents exercise - Social history - Drinking - More than one drink per day - Binge drinking on the weekends (more than 3 or 4 drinks per weekend day) - Smoking - It's OK if they were a previous smoker, but they need to have quit more than 6 months ago - Exercise - They must exercise less than one hour per week - Medications: must be on stable regimen of ANY medication for at least 3 months - Beta-Blockers - Lipid/cholesterol lowering medications: - Oral hypoglycemics (anti-diabetes medications - some like metformin are indicated for pre-diabetes) - Hormone replacement therapy - If the woman is pre-menopausal, it is OK if she is on birth control as long as she has been on it over 3 months - Weight history - Weight <300 lbs - BMI 30 to 45 - Weight stable - <10lbs weight loss or gain in the last 3 months



Primary Contact:

Principal Investigator
Samuel Klein, MD
Washington University School of Medicine

Backup Contact:


Location Contact:

St. Louis, Missouri 63110
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.